ES2378071T3 - Moduladores de cannabinoides de tetrahidro-indazol - Google Patents

Moduladores de cannabinoides de tetrahidro-indazol Download PDF

Info

Publication number
ES2378071T3
ES2378071T3 ES05732229T ES05732229T ES2378071T3 ES 2378071 T3 ES2378071 T3 ES 2378071T3 ES 05732229 T ES05732229 T ES 05732229T ES 05732229 T ES05732229 T ES 05732229T ES 2378071 T3 ES2378071 T3 ES 2378071T3
Authority
ES
Spain
Prior art keywords
compound
hydroxy
phenyl
optionally substituted
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05732229T
Other languages
English (en)
Spanish (es)
Inventor
Bharat Lagu
Fina Liotta
Meng Pan
Michael P. Wachter
Mingde Xia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34965110&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2378071(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of ES2378071T3 publication Critical patent/ES2378071T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES05732229T 2004-03-24 2005-03-23 Moduladores de cannabinoides de tetrahidro-indazol Expired - Lifetime ES2378071T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55589004P 2004-03-24 2004-03-24
US555890P 2004-03-24
PCT/US2005/009819 WO2005095353A1 (en) 2004-03-24 2005-03-23 Tetrahydro-indazole cannabinoid modulators

Publications (1)

Publication Number Publication Date
ES2378071T3 true ES2378071T3 (es) 2012-04-04

Family

ID=34965110

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05732229T Expired - Lifetime ES2378071T3 (es) 2004-03-24 2005-03-23 Moduladores de cannabinoides de tetrahidro-indazol

Country Status (22)

Country Link
US (2) US7452997B2 (enExample)
EP (1) EP1735286B1 (enExample)
JP (1) JP4825792B2 (enExample)
CN (1) CN1956964B (enExample)
AR (1) AR048341A1 (enExample)
AT (1) ATE540027T1 (enExample)
AU (1) AU2005228868B2 (enExample)
BR (1) BRPI0509207A (enExample)
CA (1) CA2561305C (enExample)
CR (1) CR8701A (enExample)
DK (1) DK1735286T3 (enExample)
EA (1) EA010887B1 (enExample)
EC (1) ECSP066877A (enExample)
ES (1) ES2378071T3 (enExample)
IL (1) IL178290A0 (enExample)
MX (1) MXPA06011017A (enExample)
NO (1) NO20064810L (enExample)
PL (1) PL1735286T3 (enExample)
PT (1) PT1735286E (enExample)
TW (1) TW200602324A (enExample)
WO (1) WO2005095353A1 (enExample)
ZA (1) ZA200608808B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2875230A1 (fr) * 2004-09-13 2006-03-17 Sanofi Aventis Sa Derives de pyrazole condense, leur preparation et leur application en therapeutique
US7888381B2 (en) 2005-06-14 2011-02-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
RS51298B (sr) * 2005-09-23 2010-12-31 Janssen Pharmaceutica N.V. Modulatori heksahidro-ciklooktil pirazol kanabinoida
CA2623745A1 (en) * 2005-09-23 2007-04-05 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
CA2623803A1 (en) 2005-09-23 2007-03-29 Janssen Pharmaceutica N.V. Tetrahydro-cyclopentyl pyrazole cannabinoid modulators
WO2007038045A1 (en) * 2005-09-23 2007-04-05 Janssen Pharmaceutica, N.V. Tetrahydro-indazolyl cannabinoid modulators
US8378117B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
US8378096B2 (en) 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
US7825151B2 (en) * 2005-09-23 2010-11-02 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl pyrazole cannabinoid modulators
US7795294B2 (en) 2006-02-14 2010-09-14 Janssen Pharmaceutica N.V. Tetrahydro-2H-indazole pyrazole cannabinoid modulators
US20070254911A1 (en) * 2006-03-27 2007-11-01 Mingde Xia Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators
US8012957B2 (en) 2006-03-27 2011-09-06 Janssen Pharmaceutica Nv Tetrahydro-1H-1,2,6-triaza-azulene cannabinoid modulators
WO2008054508A2 (en) * 2006-04-13 2008-05-08 Alza Corporation Stable nanosized amorphous drug
CN101573339A (zh) * 2006-11-03 2009-11-04 格兰马克药品股份有限公司 作为大麻素受体配体的桥接二环吲唑
EP1935420A1 (en) * 2006-12-21 2008-06-25 Merck Sante 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors
AU2008229264A1 (en) * 2007-03-21 2008-09-25 Janssen Pharmaceutica N.V. Method for treating CB2 receptor mediated pain
AU2008229265A1 (en) * 2007-03-21 2008-09-25 Janssen Pharmaceutica N.V. Method for treating CB2 receptor mediated pain
UA100120C2 (en) 2007-04-03 2012-11-26 Анадис Фармасьютикалз, Инк. 5,6-dihydro-1h-pyridin-2-one compounds
US8338623B2 (en) * 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
US7943653B2 (en) * 2007-08-13 2011-05-17 Janssen Pharmaceutica N.V. Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators
AU2009203549B2 (en) * 2008-01-08 2013-03-07 Purdue Pharma L.P. Proline Analogs as ligands for cannabinoid receptors for the treatment of pain
US20090215850A1 (en) * 2008-02-27 2009-08-27 Mingde Xia Method for treating cb2 receptor mediated pain
CN102164899B (zh) * 2008-09-25 2014-11-26 霍夫曼-拉罗奇有限公司 用作抗异常脂肪血症及相关疾病的fxr调节剂的取代的吲唑或四氢吲唑类
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10435375B2 (en) 2015-05-05 2019-10-08 Northwestern University CXCR4 chemokine receptor modulators
WO2017034872A1 (en) * 2015-08-25 2017-03-02 Janssen Pharmaceutica Nv Indazole derivatives useful as cb-1 inverse agonists
CN105367498B (zh) * 2015-11-11 2019-05-17 中国农业大学 吡唑并环-3-甲酰胺类似物及其制备和应用
CN106397218A (zh) * 2016-09-04 2017-02-15 王际菊 S‑α‑环己基苯甲胺
US20210253562A1 (en) * 2018-07-03 2021-08-19 Janssen Pharmaceutica Nv Acylsufonamide compounds useful as ep3 receptor antagonists
TWI768465B (zh) * 2019-09-12 2022-06-21 大陸商四川海思科製藥有限公司 四氫吲唑衍生物及其製備
TWI768464B (zh) * 2019-09-12 2022-06-21 大陸商四川海思科製藥有限公司 三環吡唑衍生物及其製備
CN119431335A (zh) * 2020-06-11 2025-02-14 贝达药业股份有限公司 双环化合物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1052111B (it) * 1972-02-29 1981-06-20 Acraf Acidi i benzil i h indazol 3 carbossilici sostituiti e loro derivati
US3895025A (en) * 1973-03-29 1975-07-15 Du Pont 2-Benzimidazolethiol preparation
US4851425A (en) * 1985-06-14 1989-07-25 The Upjohn Company Cyclopentapyrazole and tetrahydroindazole compounds and their use as anti-inflammatory and anti-allergic agents
US4861777A (en) * 1987-09-11 1989-08-29 Mitsubishi Kasei Corporation Pyrazole derivative and insecticidal and miticidal composition containing the derivative as active ingredient
JPH06306053A (ja) * 1993-01-29 1994-11-01 Sagami Chem Res Center ３−アゾールカルボン酸誘導体の製造方法及びその中間体
US5532237A (en) * 1995-02-15 1996-07-02 Merck Frosst Canada, Inc. Indole derivatives with affinity for the cannabinoid receptor
US6410533B1 (en) * 2000-02-10 2002-06-25 Genzyme Corporation Antibacterial compounds
EP1254115A2 (en) * 2000-02-11 2002-11-06 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
CA2464333C (en) * 2001-10-26 2011-07-26 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
CA2480856A1 (en) 2002-04-05 2003-10-23 Merck & Co., Inc. Substituted aryl amides
US7145012B2 (en) * 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof

Also Published As

Publication number Publication date
BRPI0509207A (pt) 2007-08-28
ATE540027T1 (de) 2012-01-15
EP1735286A1 (en) 2006-12-27
EP1735286B1 (en) 2012-01-04
NO20064810L (no) 2006-12-22
US7452997B2 (en) 2008-11-18
ZA200608808B (en) 2008-06-25
WO2005095353A1 (en) 2005-10-13
IL178290A0 (en) 2006-12-31
JP4825792B2 (ja) 2011-11-30
DK1735286T3 (da) 2012-04-02
JP2007530577A (ja) 2007-11-01
US20090099143A1 (en) 2009-04-16
CA2561305A1 (en) 2005-10-13
CN1956964A (zh) 2007-05-02
US20050228034A1 (en) 2005-10-13
MXPA06011017A (es) 2007-03-21
AU2005228868A1 (en) 2005-10-13
CR8701A (es) 2008-11-24
PT1735286E (pt) 2012-03-05
CN1956964B (zh) 2011-06-15
PL1735286T3 (pl) 2012-06-29
EA010887B1 (ru) 2008-12-30
AR048341A1 (es) 2006-04-19
AU2005228868B2 (en) 2012-02-09
EA200601760A1 (ru) 2007-02-27
ECSP066877A (es) 2006-11-24
CA2561305C (en) 2013-07-30
TW200602324A (en) 2006-01-16

Similar Documents

Publication Publication Date Title
ES2378071T3 (es) Moduladores de cannabinoides de tetrahidro-indazol
US20100069341A1 (en) Tetrahydro-pyranopyrazole cannabinoid modulators
ES2357776T3 (es) Moduladores de cannabionoides de tetrahidro piridinil pirazol.
ES2340201T3 (es) Moduladores de hexahidro-ciclooctilpirazol cannabinoides.
US7943653B2 (en) Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators
PT1764468E (pt) Mecanismo para um painel em vidro deslizante
JP2009508954A (ja) 置換３−アミド−テトラヒドロ−インダゾリル系カンナビノイドモジュレーター
US7795294B2 (en) Tetrahydro-2H-indazole pyrazole cannabinoid modulators
US7790718B2 (en) Tetrahydro-cyclopentyl pyrazole cannabinoid modulators
JP2009517388A (ja) 置換５−ヘテロアリール−１−フェニル−ピラゾール系カンナビノイドモジュレーター
ES2375213T3 (es) Moduladores de cannabinoides de hexadhidro-cicloheptapirazol.
KR20070018056A (ko) 테트라하이드로-인다졸 카나비노이드 조정자